SEALD With a Kiss.
Year: 2005
Type: article
Abstract: Are patient-reported outcomes (PRO) an important part of the labeling for biotechnology products? According to a recent health policy briefing by Jane A. Scott, PhD, of the U.S. Food and Drug Administration Office of New Drugs, we could soon see PRO included in the Study Endpoint and Label Development (SEALD) process (Scott 2004).
DAVID B. NASH, MD, MBA
Currently, according to the FDA, 30 percent of labels for new products report some form of PRO data. If one looks at new molecular entities (NMEs) with PRO in the approved labeling, it becomes apparent that such categories as anti-inflammatories and gastrointestinal agents lead the pack; more than 75 percent, on average, include some form of PRO. Not surprisingly, anti-infectives and anticoagulants of all types rarely have PRO-related material in their labeling.
I envision a day when even sophisticated biotechnology-derived products will include more PRO-related information. Of course, some of the challenges for PRO endpoints include details like reliability, reproducibility, and internal consistency. In addition, PRO measures may lack face validity (On its face, does it seem like a reasonable way to gain the information sought?) and predictive validity (Can the outcomes data collected accurately predict response in a larger, specific population?). It is difficult to translate self-reported information into meaningful scores. Perhaps technological innovations, such as personal digital assistants and interactive voice-recognition technology, will facilitate collection and analysis of PRO-related information.
Other challenges of analyzing PRO data include controlling for multiple comparisons, pooling data from multiple translations, and the more general problem of missing data altogether. Also, defining the so-called minimum Important Difference, or the smallest worthwhile effect, might be extremely difficult with PRO data.
Source: Europe PMC (PubMed Central)
Author: David B Nash
Language: English
Subfield: Economics and Econometrics
Domain: Social Sciences
Keywords: patient-reported outcomes, drug labeling, FDA, biotechnology products, new chemical entities, anti-inflammatory agents, gastrointestinal agents, anti-infective agents, anticoagulants, face validity, predictive validity, missing data, multiple comparisons, minimal clinically important difference, self-reported outcome measures
Open Access status: green
OpenAlex ID: W2994374321
